The International Liability Business Panel met on 21st May 2026 to discuss market developments, wordings projects, claims trends, and emerging risks. The panel reviewed progress on the Bodily Injury Index, including upcoming DACB briefing sessions covering key international territories and enhancements to data visualisation and oversight processes. Discussions continued on long-term agreement wordings, advertising liability clauses, and clarifying the distinction between deductibles and excesses to avoid claims ambiguity. Members considered life sciences market challenges, including inconsistent risk coding and data collection issues, and highlighted the need for compliance with cyber clause requirements in Australian business. Significant attention was given to AI, with discussions on developing standard AI definitions while resisting broad liability exclusions. Updates were provided on Brazilian claims cooperation clauses and forthcoming claims briefings on PFAS, microplastics and food-related exposures. Additional concerns included governing law paramount clauses, increased US bad faith litigation, claims lead clauses, claims handling fees, and undisclosed broker use of AI.